文献速递新生儿儿童血液肿瘤与免疫

PlaNeT-2试验发表前后多新生儿重症监护病房医疗组织中的血小板输注变化

Platelet Transfusions in a Multi-Neonatal Intensive Care Unit Health Care Organization Before and After Publication of the PlaNeT-2 Clinical Trial.
PubMed 文献 · J Pediatr · 2023-03-16

该多NICU回顾性分析评估在PlaNeT-2试验发表后实施更严格的血小板输注指南(多数新生儿阈值从50 000/μL改为25 000/μL)是否与接受血小板输注的NICU患者减少相关且不恶化结局。结果显示输注率从15.9/1000降至12.9/1000(P=.106),触发输注的平均血小板计数从43 100/μL降至38 000/μL(P=.044),不良结局发生率无变化,但接受输注的新生儿数未显著减少。

要点

  • 更严格指南实施后,血小板输注率从15.9/1000降至12.9/1000,差异无统计学意义(P=.106)。
  • 触发输注的平均血小板计数从43 100/μL降至38 000/μL(P=.044)。
  • 不良结局发生率无变化,提示更严格实践未增加不良结局。

核心结论

  • 在多NICU网络中实施更严格的血小板输注指南与接受输注的新生儿数显著减少无关。
  • 指南实施与触发输注的平均血小板计数降低相关。
  • 不良结局发生率无变化。

研究设计与样本

  • 多NICU回顾性分析,比较系统范围指南修订前3年与后3年的血小板输注、患者特征和结局。

主要发现

  • 第一时期130名新生儿接受至少1次血小板输注,第二时期降至106名。
  • 输注率第一时期为15.9/1000 NICU入院,第二时期为12.9/1000(P=.106)。
  • 第二时期血小板计数在50 000-100 000/μL范围时输注比例更小(P=.017),<25 000/μL时输注比例更大(P=.083)。
  • 触发输注前的血小板计数从43 100/μL降至38 000/μL(P=.044)。
  • 不良结局发生率无变化。

关键数值与推荐

  • PlaNeT-2试验后多数新生儿血小板输注阈值从50 000/μL改为25 000/μL。

临床怎么用

  • 实施更严格的血小板输注指南可降低触发输注的血小板计数且未增加不良结局。
  • 需额外教育和问责追踪以进一步安全减少血小板输注。

局限性

  • 回顾性分析设计。
  • 接受血小板输注的新生儿数减少无统计学意义(P=.106)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether implementing more restrictive neonatal intensive care unit (NICU) platelet transfusion guidelines following the Platelets for Neonatal Transfusion - Study 2 randomized controlled trial (transfusion threshold changed from 50 000/μL to 25 000/μL for most neonates) was associated with fewer NICU patients receiving a platelet transfusion, without adversely affecting outcomes. STUDY DESIGN: Multi-NICU retrospective analysis of platelet transfusions, patient characteristics, and outcomes during 3 years before vs 3 years after revising system-wide guidelines. RESULTS: During the first period, 130 neonates received 1 or more platelet transfusions; this fell to 106 during the second. The transfusion rate was 15.9/1000 NICU admissions in the first period vs 12.9 in the second (P = .106). During the second period, a smaller proportion of transfusions was administered when the platelet count was in the 50 000-100 000/μL range (P = .017), and a larger proportion when it was <25 000/μL (P = .083). We also saw a fall in the platelet counts that preceded the order for transfusion from 43 100/μL to 38 000/μL (P = .044). The incidence of adverse outcomes did not change. CONCLUSIONS: Changing platelet transfusion guidelines in a multi-NICU network to a more restrictive practice was not associated with a significant reduction in number of neonates receiving a platelet transfusion. The guideline implementation was associated with a reduction in the mean platelet count triggering a transfusion. We speculate that further reductions in platelet transfusions can safely occur with additional education and accountability tracking.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Bahr TM, Christensen TR, Henry E, et al. Platelet Transfusions in a Multi-Neonatal Intensive Care Unit Health Care Organization Before and After Publication of the PlaNeT-2 Clinical Trial. J Pediatr. 2023. PMID: 36933765. doi:10.1016/j.jpeds.2023.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。